(Q35633680)

English

Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

scientific article published on January 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 (English)

1 reference

Europe PubMed Central

9 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Gloria Broadwater

2

object named as

Gloria Broadwater

1 reference

Europe PubMed Central

9 August 2017

12

object named as

Eric P Winer

1 reference

Europe PubMed Central

9 August 2017

3

object named as

Nancy U Lin

1 reference

Europe PubMed Central

9 August 2017

author name string

Lyndsay N Harris

1

1 reference

Europe PubMed Central

9 August 2017

Alexander Miron

4

1 reference

Europe PubMed Central

9 August 2017

Stuart J Schnitt

5

1 reference

Europe PubMed Central

9 August 2017

David Cowan

6

1 reference

Europe PubMed Central

9 August 2017

Jonathan Lara

7

1 reference

Europe PubMed Central

9 August 2017

Ira Bleiweiss

8

1 reference

Europe PubMed Central

9 August 2017

Donald Berry

9

1 reference

Europe PubMed Central

9 August 2017

Matthew Ellis

10

1 reference

Europe PubMed Central

9 August 2017

Daniel F Hayes

11

1 reference

Europe PubMed Central

9 August 2017

Lynn Dressler

13

1 reference

Europe PubMed Central

9 August 2017

publication date

1 January 2006

1 reference

Europe PubMed Central

9 August 2017

Breast Cancer Research

1 reference

Europe PubMed Central

9 August 2017

8

1 reference

Europe PubMed Central

9 August 2017

R66

1 reference

Europe PubMed Central

9 August 2017

6

1 reference

Europe PubMed Central

9 August 2017

https://scigraph.springernature.com/pub.10.1186/bcr1622

0 references

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

Cancer statistics, 2004

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

Predicting the clinical status of human breast cancer by using gene expression profiles

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

Molecular portraits of human breast tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

Future directions of paclitaxel-based therapy of breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

12 July 2018

Reporting recommendations for tumor marker prognostic studies (REMARK).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

25 September 2018

Adjuvant docetaxel for node-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

25 September 2018

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

25 September 2018

Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

25 September 2018

Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

25 September 2018

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

25 September 2018

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

25 September 2018

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

25 September 2018

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

25 September 2018

Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

25 September 2018

Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

25 September 2018

Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

25 September 2018

Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1797029

25 September 2018

1 reference

https://api.crossref.org/works/10.1186%2FBCR1622

21 January 2018

Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over

1 reference

https://pubmed.ncbi.nlm.nih.gov/17129383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benefit of Paclitaxel in estrogen receptor-negative versus estrogen receptor-positive early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17129383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17129383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17129383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17129383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17129383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/BCR1622

1 reference

Europe PubMed Central

9 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35633680&oldid=1966921213"